Brief: NurExone Biologic Announces Preclinical Evidence of Structural Repair In Injured Spinal Cord Tissue Following ExoPTEN Treatment
20/08/2025 21:04
Aug 20 (Reuters) - Nurexone Biologic Inc NRX.V: NUREXONE BIOLOGIC ANNOUNCES PRECLINICAL EVIDENCE OF STRUCTURAL REPAIR IN INJURED SPINAL CORD TISSUE FOLLOWING EXOPTEN TREATMENT Source text: ID:nGNX3NPQ9n Further company coverage: NRX.V ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement